Posts
December 09 2023
Biodexa Pharmaceuticals Plc announced the closing of its Underwritten Public Offering in the amount of $6,000,000. EG&S acted as counsel to the Underwriter.
December 05 2023
POET Technologies Inc. announced the closing of its Underwritten Public Offering of Common Shares and Warrants in the amount of $1,600,000. EG&S acted as counsel to the Underwriter.
December 04 2023
Netcapital Inc. announced the closing of its Public Offering in the amount of $4,000,000. EG&S acted as counsel to the Placement Agent.
December 01 2023
Moleculin Biotech, Inc. announced the closing of its Registered Direct offering in the amount of $4,500,000. EG&S acted as counsel to the Placement Agent.
December 01 2023
BIOLASE, Inc. announced the closing of its Registered Direct offering in the amount of $1,400,000. EG&S acted as counsel to the Placement Agent.
November 29 2023
Client Alert: New Regulations Affecting New York City Employers’ Obligation to Provide Paid Time Off
The New York City Department of Consumer and Worker Protection recently issued amendments to the rules implementing New York City’s Earned Safe and Sick Time Act (“ESSTA”).
Click here to read the alert.
November 28 2023
Fortress Biotech, Inc. announced the closing of its Public Offering in the amount of $10,00,000. EG&S acted as counsel to the Placement Agent.
November 28 2023
Veea Inc., a digital transformation company, and Plum Acquisition Corp. I, a Cayman Islands exempted company formed as a special purpose acquisition company, announced their entry into a definitive business combination agreement related to a proposed merger expected to result in Veea becoming a publicly traded company whose business, after the closing, assuming the occurrence thereof, will be the continued business of Veea. EGS acted as counsel to Veea Inc.